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Objective: We sought to determine whether chemoradiotherapy after esophagec-
tomy improves survival.
Methods: From 1994 to 2000, 31 patients with locoregionally advanced esophageal
carcinoma (90% pT3, 81% pN1, and 13% pM1a) received postoperative adjuvant
chemoradiotherapy. Concurrently, 52 patients with advanced carcinoma underwent
esophagectomy alone and survived at least 10 weeks, the time frame for adjuvant
therapy. A propensity score based on demographic, tumor, and surgical factors was
used to identify matched pairs to determine the association of adjuvant therapy with
outcomes.
Results: For patients receiving adjuvant therapy versus esophagectomy alone,
risk-unadjusted median, 1-year, and 4-year survivals were 28 versus 14 months,
68%  8.4% versus 60%  6.8%, and 44%  9.0% versus 17%  5.6%,
respectively (P .05). Similarly, risk-unadjusted median time to recurrence was 25
versus 13 months (P  .15), and median recurrence-free survival was 22 versus 11
months (P  .04). Among propensity-matched patients, median, 1-year, and 4-year
survivals for those receiving adjuvant therapy versus esophagectomy were 28 versus
15 months, 60%  11.0% versus 65%  10.7%, and 44%  11.3% versus 0% (P
 .05). Median time to recurrence was 25 versus 13 months (P  .04), and
recurrence-free survival was 22 versus 10 months (P  .02).
Conclusion: In patients with locoregionally advanced esophageal carcinoma, addi-
tion of postoperative adjuvant chemoradiotherapy to esophagectomy alone doubled
survival time, time to recurrence, and recurrence-free survival. Patients with locore-
gionally advanced carcinoma after esophagectomy should be considered for adju-
vant therapy.
Postoperative adjuvant therapy provides a survival advantage in can-cers of the stomach, colon, and rectum.1-3 However, single-modalitypostoperative adjuvant therapy in esophageal cancer has been limitedand potentially harmful,4-6 although postoperative adjuvant radiationtherapy may benefit patients with advanced disease.7 Recent clinicalexperience with modern postoperative adjuvant chemoradiotherapy
suggests a survival benefit compared with historical controls.8,9 In the absence of
randomized trials, the purpose of this study was to determine whether adjuvant
chemoradiotherapy after esophagectomy improves survival compared with esoph-
agectomy alone.
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Patients and Methods
Patients
From 1994 to 2000, 31 patients with pathologically documented
locoregionally advanced adenocarcinoma or squamous cell esoph-
ageal carcinoma (T3-4, N1, or M1a) underwent esophagectomy
and were entered in an institutional review board–approved (IRB
4624) trial of postoperative adjuvant chemoradiotherapy. Patients
were eligible for this protocol if they had not received previous
radiation or chemotherapy for this cancer, had an Eastern Coop-
erative Oncology Group performance status of 0 or 1, a white
blood cell count of 3000 · mm3 or greater, and a serum creatinine
level of 2.0 mg · dL1 or less.
During this period, 52 patients with locoregionally advanced
carcinoma underwent esophagectomy alone without adjuvant ther-
apy and survived more than 10 weeks after the operation, the time
frame for postoperative adjuvant therapy (Tables 1 and 2). Data
used for this study came from the Cleveland Clinic esophageal
database, which has been approved for research by the institutional
review board.
Esophagectomy
Esophagectomy with thoracotomy and 2-field lymphadenectomy
was performed in 27 patients receiving adjuvant therapy and 46
patients receiving esophagectomy alone. Four patients receiving
adjuvant therapy and 6 patients receiving esophagectomy alone
had transhiatal esophagectomy and lymph node sampling. Gastro-
intestinal reconstruction in all patients used the stomach, with
esophagogastric anastomosis done in the neck.
Postoperative Adjuvant Chemoradiotherapy
Three to 10 weeks after esophagectomy, each patient received a
continuous course of external beam radiation therapy with concur-
rent chemotherapy. Patients received 50.4 to 59.4 Gy in 1.8-Gy
once-daily fractions. Treatments were delivered using a linear
accelerator with 6- to 8-MV photons at a distance of 100 cm from
the source to the axis of rotation. Computed tomography–based
treatment planning was used in all patients. A minimum 5-cm
margin was given to the tumor bed, superiorly and inferiorly.
Lymph node coverage included mediastinal and celiac lymph
nodes for middle thoracic tumors and low mediastinal and celiac
lymph nodes for lower thoracic tumors. The maximal spinal dose
was 45 Gy, which was accomplished either by a field rearrange-
ment after 39.6 to 41.4 Gy or by treatment with a 3-field technique
from the beginning of therapy.
Concurrent with radiotherapy, each patient received two 4-day
cycles of intravenous 5-fluorouracil (1000 mg · m2 · d1) and
cisplatin (20 mg · m2 · d1) during the first and fourth week of
adjuvant therapy. After completion of chemoradiotherapy, patients
were followed at 3-month intervals.
Comparison of Outcome
Management of outcome data. Because patients had to sur-
vive esophagectomy to receive postoperative adjuvant therapy,
those undergoing esophagectomy alone who died within 10 weeks
of the operation were not included in this comparative study. Thus,
in both groups, 10 weeks postoperatively was taken as time zero
for all time-related analysis.
Both Kaplan–Meier (nonparametric) and Cox proportional haz-
ards analyses were used to compare survival, freedom from recur-
rence, and recurrence-free survival between patients receiving
adjuvant therapy and those receiving esophagectomy alone. Non-
parametric survival estimates were compared by using the log-rank
test. Survival estimates are presented with their SE and number of
patients at various intervals and as median survival.
Methods of comparisons. Outcomes were compared in 2
ways: risk unadjusted and propensity matched.
Risk-unadjusted comparison of outcomes among patients re-
ceiving postoperative adjuvant chemoradiotherapy versus esopha-
gectomy alone was performed using the log-rank statistic.
Propensity-matched comparison was performed because selec-
tion of patients for adjuvant therapy or esophagectomy alone was
not random.10,11 Therefore, the probability of receiving adjuvant
therapy versus esophagectomy alone was estimated by logistic
regression using 15 variables representing 13 patient, tumor, pro-
cedure, and experience characteristics: sex, race, age at operation,
pT (T2 vs T1 and T3-4 vs T1, 2 variables), pN, total number of
TABLE 1. Comparison of patients undergoing postoperative
adjuvant therapy with those undergoing esophagectomy
alone: Categorical variables
Variable
Adjuvant
therapy
(n  31)
Esophagectomy
alone
(n  52) P
valueNo. % No. %
Sex .5
Female 3 10 8 15
Male 28 90 44 85
Race .9
White 30 97 50 96
Other 1 3 2 4
pT .3
pT1 2 6 2 4
pT2 1 3 2 4
pT3 28 90 43 83
pT4 0 0 5 10
pN .6
pN0 6 19 13 25
pN1 25 81 39 75
pM .4
pM0 27 87 46 88
pM1a 4 13 4 8
pM1b 0 0 2 4
Histopathologic type .9
Adenocarcinoma 26 84 43 83
Squamous cell carcinoma 5 16 9 17
Histopathologic grade .97
Poorly differentiated 21 68 36 69
Moderately differentiated 9 29 14 27
Well differentiated 1 3 2 4
Completeness of resection .6
R1 8 26 11 21
R0 23 74 41 79
Surgical approach .8
Thoracotomy 27 87 46 88
Transhiatal 4 13 6 12
Rice et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 5 1591
G
TS
lymph nodes resected, total number of resected nodes containing
metastatic cancer, pM, histopathologic type (adenocarcinoma vs
squamous cell carcinoma), histopathologic grade (moderately vs
well and poorly vs well differentiated, 2 variables), surgical ap-
proach (thoracotomy vs transhiatal), completeness of resection (R0
vs R1), and date of operation. A propensity score was calculated
for each patient from the resulting logistic regression equation.
Patients undergoing each therapy were then matched by using the
above propensity score.12 Because the original 2 groups were of
comparable size, there were too few esophagectomy-only patients
to match every patient receiving postoperative adjuvant chemo-
radiotherapy. Thus, 20 well-matched pairs of patients were avail-
able for comparison of outcomes (Tables 3 and 4) by using the
log-rank and hazard ratio statistics.
Presentation
Continuous variables are presented as means  1 SD. Survival
estimates are presented as percentage  1 SE. For consistency
with these, hazard ratios are presented with 68% confidence limits
(CL).
Results
Toxicity
Toxicity of the adjuvant chemoradiotherapy is detailed in
Table 5. Nutrition was well maintained during adjuvant
therapy in part because 28 of the 31 patients had jejunos-
tomy tubes in place throughout treatment. There were no
toxic deaths. Unplanned hospitalizations were required in 9
patients: 3 because of uncomplicated neutropenic fever, 2
because of a venous thromboembolic event, 2 because of
infections developing with adequate blood counts, and 1
each with presumably unrelated episodes of ischemic colitis
and cholecystitis.
TABLE 3. Comparison of propensity-matched patients un-
dergoing postoperative adjuvant therapy with those under-
going esophagectomy alone: Categoric variables
Variable
Adjuvant
therapy
(n  20)
Esophagectomy
alone
(n  20) P
valueNo. % No. %
Sex .6
Female 2 10 3 15
Male 18 90 17 85
Race .3
White 20 100 19 95
Other 0 0 1 5
pT .4
pT2 1 5 1 5
pT3 19 95 17 85
pT4 0 0 2 10
pN .7
pN0 5 25 6 30
pN1 15 75 14 70
pM .2
pM0 18 90 19 95
pM1a 2 10 0 0
pM1b 0 0 1 5
Histopathologic type 1
Adenocarcinoma 16 80 16 80
Squamous cell carcinoma 4 20 4 20
Histopathologic grade .2
Poor 10 50 15 75
Moderate 9 45 4 20
Well 1 5 1 5
Completeness of resection 1
R1 4 20 4 20
R0 16 80 16 80
Surgical approach .6
Thoracotomy 17 85 18 90
Transhiatal 3 15 2 10
TABLE 2. Comparison of patients undergoing postoperative adjuvant therapy with those undergoing esophagectomy alone:
Continuous variables
Variable/group No. Mean  SD Minimum Median Maximum P value
Age at operation .001
Adjuvant therapy 31 57 10 55 33 76
Esophagectomy alone 52 65 10 66 36 90
Total no. of resected lymph nodes .6
Adjuvant therapy 31 17 10 17 2 50
Esophagectomy alone 52 16 10 14 0 39
Total no. of resected lymph nodes containing
metastatic cancer*
.9
Adjuvant therapy 25 6.1 4.7 5 1 18
Esophagectomy alone 39 5.9 5.7 3 1 27
Date of operation (years relative to Jan 1, 1994) .001
Adjuvant therapy 31 4.5 1.3 4.5 0.9 6.9
Esophagectomy alone 52 2.9 1.9 2.6 0.1 6.6
Propensity score .001
Adjuvant therapy 31 0.56 0.21 0.55 0.14 0.90
Esophagectomy alone 52 0.26 0.24 0.16 0 0.91
*For patients with pN1 disease.
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Outcome
Survival. For patients receiving adjuvant therapy versus
esophagectomy alone, risk-unadjusted median, 1-year, and
4-year survivals were 28 months versus 14 months, 68% 
8.4% versus 60%  6.8%, and 44%  9.0% versus 17% 
5.6%, respectively (P .05; Figure 1, A). Among propensity-
matched patients, median, 1-year, and 4-year survivals in
the 2 groups of patients were 28 months versus 15 months,
60%  11.0% versus 65%  10.7%, and 44%  11.3%
versus 0%, respectively (P  .05; Figure 1, B). The hazard
ratio of adjuvant therapy versus esophagectomy was 0.46
(CL 0.31-0.69).
Recurrence. There were 17 recurrences in patients re-
ceiving adjuvant chemoradiotherapy. One patient was alive
and disease free at follow-up after resection of a solitary
brain metastasis. Sixteen patients died with disease: 7 with
local metastases, 7 with distant metastases, and 2 with both
local and distant metastases. There were 33 cancer recur-
rences in patients receiving esophagectomy alone. Two
were alive at follow-up, one with local and one with distant
recurrence. Thirty-one died with disease: 14 with local
metastases, 12 with distant metastases, and 5 with both local
and distant metastases. Among the 20 propensity-matched
patients receiving adjuvant therapy, 12 had recurrences, 4
local and 8 distant. Of the 20 receiving esophagectomy
alone, 16 had recurrences, 6 local, 8 distant, and 2 both local
and distant.
For patients receiving adjuvant therapy versus esopha-
gectomy alone, risk-unadjusted median, 1-year, and 4-year
freedoms from recurrence were 25 months versus 13
months, 65%  8.6% versus 53%  7.4%, and 44% 
9.8% versus 23%  7.0%, respectively (P  .15; Figure 2,
A). Among propensity-matched patients, median, 1-year,
and 4-year freedoms from recurrence in the 2 groups of
patients were 25 months versus 13 months, 60%  11.0%
versus 50%  1.9%, and 40%  12.1% versus 0%, respec-
tively (P  .04; Figure 2, B). The hazard ratio of adjuvant
therapy versus esophagectomy was 0.45 (CL 0.30-0.67).
Recurrence-free survival. For patients receiving adju-
vant therapy versus esophagectomy alone, risk-unadjusted
median, 1-year, and 4-year recurrence-free survivals were
22 months versus 11 months, 61%  8.8% versus 42% 
6.8%, and 39%  9.3% versus 15%  5.0%, respectively
(P  .04; Figure 3, A). For propensity-matched patients,
median, 1-year, and 4-year recurrence-free survivals in the
2 groups of patients were 22 months versus 10 months, 55%
 11.1% versus 40%  11.0%, and 37%  11.6% versus
0%, respectively (P  .02; Figure 3, B). The hazard ratio of
adjuvant therapy versus esophagectomy was 0.42 (CL
0.29-1.62).
Discussion
Rationale for Adjuvant Therapy
Single-modality preoperative adjuvant therapy (chemother-
apy or radiotherapy) for esophageal carcinoma offers no
TABLE 5. Toxicity of adjuvant chemoradiotherapy
Toxicity No. %
Nausea 31 100
Severe, grade 3-4 3 10
Mucositis/dysphagia 17 55
Severe, grade 3-4 6 19
Neutropenia 1000 · mm3 9 29
With fever 3 10
Thrombocytopenia 20,000 · mm3 2 6
Unplanned hospitalization 9 29
Toxic death 0 0
TABLE 4. Comparison of propensity-matched patients undergoing postoperative adjuvant therapy with those undergoing
esophagectomy alone: Continuous variables
Variable/group No. Mean  SD Minimum Median Maximum P value
Age at operation .7
Adjuvant therapy 20 59 10 58 41 76
Esophagectomy alone 20 60 10 59 36 77
Total no. of resected lymph nodes .4
Adjuvant therapy 20 13 7 12 2 24
Esophagectomy alone 20 15 9 13 3 37
Total no. of resected lymph nodes containing
metastatic cancer*
.16
Adjuvant therapy 15 5.6 3.6 5 1 14
Esophagectomy alone 14 3.6 3.8 2 1 15
Date of operation (years relative to Jan 1, 1994) .5
Adjuvant therapy 20 4.3 1.5 4.2 0.9 6.9
Esophagectomy alone 20 4.6 1.3 4.8 2.1 6.6
Propensity score .9
Adjuvant therapy 20 0.49 0.21 0.47 0.14 0.86
Esophagectomy alone 20 0.49 0.21 0.50 0.14 0.91
*For patients with pN1 disease.
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greater survival than esophagectomy alone.13-15 Concurrent
preoperative chemoradiotherapy has produced conflicting
results despite complete pathologic response in up to 30%
of patients.16-18 Single-modality postoperative adjuvant
therapy has not improved survival or has been harmful,4-6
except for a recent report of benefit from radiation therapy
for stage IIB or III tumors.7 However, recent phase II
studies8,9 and this report suggest that postoperative concur-
rent chemoradiotherapy improves survival compared with
historical controls and propensity-matched patients receiv-
ing esophagectomy alone. It can be administered with ac-
ceptable toxicity and enhances local control in patients with
locoregionally advanced esophageal carcinoma.
Postoperative adjuvant therapy has theoretic advantages
and disadvantages. Potential advantages include the follow-
ing: (1) therapy can be based on pathologic stage rather than
potentially inaccurate clinical stage; (2) patients who might
benefit from adjuvant therapy can be identified, avoiding
toxicity in those who do not need or will not benefit from it;
(3) delay resulting from induction therapy is avoided, and
resection is ensured; (4) dysphagia is relieved early in
treatment; (5) nutrition can be maintained with feeding
Figure 1. Survival among patients receiving adjuvant therapy
compared with esophagectomy alone. Long vertical bars repre-
sent CLs of 1 SE. Short vertical bars represent censored patients.
Each step in the graph represents an event. A, Unadjusted. Num-
bers of patients traced at 0, 1, and 4 years were 31, 21, and 5 in
the adjuvant therapy group and 52, 31, and 5 in the esophagec-
tomy-alone group. B, Propensity matched. Numbers of patients
traced at 0, 1, and 4 years were 20, 12, and 3 in the adjuvant
therapy group and 20, 13, and 0 in the esophagectomy-alone
group.
Figure 2. Freedom from recurrence among patients receiving
adjuvant therapy compared with esophagectomy alone. Format is
as shown in Figure 1. A, Unadjusted. Numbers of patients traced
at 0, 1, and 4 years were 31, 19, and 5 in the adjuvant therapy
group and 52, 22, and 5 in the esophagectomy-alone group. B,
Propensity matched. Numbers of patients traced at 0, 1, and 4
years were 20, 11, and 3 in the adjuvant therapy group and 20, 8,
and 0 in the esophagectomy-alone group.
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tubes placed at operation; and (6) induction therapy toxicity
does not affect surgery. Potential disadvantages include the
following: (1) blood supply to the resected area is reduced,
decreasing delivery of chemotherapy to the locoregional
tumor bed; (2) the radiation therapy target is removed at
operation, complicating the definition of radiation fields; (3)
postoperative complications preclude adjuvant therapy; (4)
early postoperative death precludes adjuvant therapy, pos-
sibly biasing survival data; and (5) the effect of induction
therapy on resectability is eliminated.
Postoperative chemoradiotherapy requires balancing ad-
vantages with disadvantages and treatment toxicity with
improved survival. For the majority of patients in this re-
port, postoperative chemoradiotherapy was advantageous.
However, when to use this strategy is not clearly defined.
Treatment Strategies
A single-treatment strategy for all patients with locoregion-
ally contained esophageal carcinoma is an outdated ap-
proach.19 Detection of cancer at an earlier stage with Barrett
surveillance, accurate clinical staging, and development of
new treatments allows a tailored stage-dependent approach
to be used.
At one end of the cancer spectrum—high-grade dyspla-
sia and intramucosal cancers without regional lymph node
metastases—esophagectomy alone offers excellent surviv-
al.20 For these patients, the toxicity of adjuvant therapy
outweighs any small survival advantage.21
At the opposite end of the cancer spectrum—marginally
operable tumors because of either bulky T3 or T4 disease or
significant regional lymph node metastases (R2 resection
likely)—esophagectomy alone offers no hope of cure. In-
duction therapy will downstage about one third of these
patients, and subsequent resection will offer responders an
intermediate survival.22 The survival advantage in respond-
ers far outweighs the toxicity of treatment. If nonresponders
are identified after induction therapy, esophagectomy might
be avoided and best palliation offered. In the future, iden-
tification of likely responders before therapy will further
refine this approach.
Esophageal carcinoma between these 2 ends of the spec-
trum affects many patients, with variable survival after
esophagectomy alone. Esophagectomy followed by postop-
erative adjuvant therapy should be considered in the follow-
ing clinical situations: (1) patients with incorrect clinical
staging who have esophagectomy and are found to have
more advanced disease (T3 or N1 or M1a); (2) patients with
T3 or N1 cancers (few regional nodal metastases) who
appear technically resectable (R0 resection possible); and
(3) patients with deep submucosal invasion (T1bN0M0) or
invasion into the muscularis propria (T2N0M0) without
regional nodal metastases.
Strengths and Weaknesses
This is a small, single-institution, nonrandomized phase II
study. Two methods of comparison were used, unadjusted
and propensity matched to minimize selection bias. Results
were consistent. Because esophagectomy was the first treat-
ment, accurate pathologic stage was available for all pa-
tients and is fundamental to this comparison, unlike preop-
erative induction therapies in which potentially inaccurate
clinical staging complicates comparisons. The absence of
staging inaccuracies and good matching based on 15 vari-
ables allowed outcome comparisons to be influenced prin-
cipally by postoperative adjuvant therapy. Nevertheless,
Figure 3. Freedom from recurrence or death (recurrence-free
survival) among patients receiving adjuvant therapy compared
with esophagectomy alone. Format is as shown in Figure 1. A,
Unadjusted. Numbers of patients traced at 0, 1, and 4 years were
31, 19, and 5 in the adjuvant therapy group and 52, 22, and 5 in the
esophagectomy-alone group. B, Propensity matched. Numbers of
patients traced at 0, 1, and 4 years were 20, 11, and 3 in the
adjuvant therapy group and 20, 8, and 0 in the esophagectomy-
alone group.
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propensity matching does not guard against unknown fac-
tors. Among potential and unmeasured factors that might
have influenced patient selection were subjective ones, such
as vigor, mental status, ability to cooperate with and consent
to treatment protocols, referral and physician bias, and the
unblinded nature of the treatments. These factors influence
not only nonrandomized comparisons but also randomized
trials.23
Clinical Inference
In patients with locoregionally advanced esophageal cancer
in whom an R0 resection is clinically possible, the strategy
of esophagectomy followed by postoperative adjuvant che-
moradiotherapy should be considered. Compared with
esophagectomy alone, it improves survival, decreases recur-
rent cancer, and increases recurrence-free survival.
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